(4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-2-chlorophenyl)boronic acid

Catalog No. :
ACZVUE958
CAS No. :
2377608-54-1
Molecular Formula :
C15H22BClN2O4
Molecular Weight :
340.62

IUPAC Name:(4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-chlorophenyl)boronic acid

(4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-2-chlorophenyl)boronic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg98%$108.00Login to see priceInquiryInquiry
1g98%$269.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-2-chlorophenyl)boronic acid
IUPAC Name(4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-chlorophenyl)boronic acid
MDL No.MFCD28369562
Molecular FormulaC15H22BClN2O4
Molecular Weight340.62
SMILESOB(C1=CC=C(N2CCN(C(OC(C)(C)C)=O)CC2)C=C1Cl)O
InChI KeyWZULTQKYFIKEBZ-UHFFFAOYSA-N
Synonym4-(4-BOC-Piperazino)-2-chlorophenylboronic acid
CAS No.2377608-54-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACZVUE958 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACASHQ536 route compound structure diagram
    ACASHQ5361046861-20-4 In Stock
  4. Then
  5. ACZVUE958 route product structure diagram
    ACZVUE9582377608-54-1
Inquiry

2. ACZVUE958 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACGHKC341 route compound structure diagram
    ACGHKC341313545-72-1 In Stock
  4. Then
  5. ACZVUE958 route product structure diagram
    ACZVUE9582377608-54-1
Inquiry

Comments (0)